SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?


To: Anthony Wong who wrote (1339)1/21/1999 12:51:00 PM
From: Anthony Wong  Read Replies (2) | Respond to of 1722
 
Warner-Lambert Reiterated Near-Term 'Buy' at Merrill

Bloomberg News
January 21, 1999, 11:58 a.m. ET

Princeton, New Jersey, Jan. 21 (Bloomberg Data) -- Warner-Lambert Co.
(WLA US) was reiterated near-term ''buy'' by analyst Steven C. Tighe at
Merrill Lynch & Co. The long-term rating was reiterated ''buy.''

-- Michael O. Donohue in Princeton, New Jersey, (609)279-3156




To: Anthony Wong who wrote (1339)1/22/1999 3:27:00 AM
From: Henry Niman  Respond to of 1722
 
Bloomberg is reporting that Sankyo's share price hit a three year low today amid growing Rezulin concerns. Merrill Lynch Japan pharmacuetical analyst Hiroshi Nakagaw indicated ''An increasing number of doctors are choosing not to prescribe Rezulin.'' Details linked to Ligand Diabetes page at biocognizance.com